CAJ | 학술논문

目的:研究天然植物苦豆子的生物碱衍生物9002#对IRM-2纯系小鼠淋巴瘤及乳腺癌的体内抑瘤作用.方法:建立荷瘤小鼠模型,以腹腔给药方式给予2个不同剂量的药物水溶液,观察瘤质量和体质量,测定抑瘤率.结果:经重复试验,9002#有一定的抑瘤作用.对淋巴瘤,剂量50 mg/(kg·d)×10天,抑瘤率51.3%～53.5%(t=4.04,3.30;P均＜0.01);剂量150mg/(kg·d)×10天,抑瘤率31.3%～35.7%(t=2.22,2.49;P均＜0.05).对乳腺癌,剂量50 mg/(kg·d)×10天,抑瘤率57.1%(t=2.63;P＜0.01);剂量150 mg/(kg·d)×10天,抑瘤率48.6%(t=2.19;P＜0.01).结论:9002#对IRM-2纯系小鼠移植肿瘤有一定的抑制作用,尤以50mg/(kg·d)×10天剂量组对移植瘤效果较明显,有潜在的临床应用价值.
목적:연구천연식물고두자적생물감연생물9002#대IRM-2순계소서림파류급유선암적체내억류작용.방법:건립하류소서모형,이복강급약방식급여2개불동제량적약물수용액,관찰류질량화체질량,측정억류솔.결과:경중복시험,9002#유일정적억류작용.대림파류,제량50 mg/(kg·d)×10천,억류솔51.3%～53.5%(t=4.04,3.30;P균＜0.01);제량150mg/(kg·d)×10천,억류솔31.3%～35.7%(t=2.22,2.49;P균＜0.05).대유선암,제량50 mg/(kg·d)×10천,억류솔57.1%(t=2.63;P＜0.01);제량150 mg/(kg·d)×10천,억류솔48.6%(t=2.19;P＜0.01).결론:9002#대IRM-2순계소서이식종류유일정적억제작용,우이50mg/(kg·d)×10천제량조대이식류효과교명현,유잠재적림상응용개치.
AIM: To investigate the inhibiting effects of 9002#, a derivative of alkaloids from Sophora alopecrokdes, on lymphoma and mammary adenoma. METHODS: Sixty-three IRM-2 inbred strain mice were inoculated with lymphoma and mammary adenoma respectively. 9002#, at the doses of 50 mg/kg per day × 10 days and 150 mg/kg per day × 10 days were injected intraperitoneally. The changes of body mass and tumor mass were scaled, and the inhibiting rates were analyzed. RESULTS: The lymphoma-inhibiting rate of 9002# at the dosage of 50 mg/kg once a day×10 days was 51.3% -53.5% (t=4.04, 3.30, P ＜0.01), and that of 9002# at the dosage of 150 mg/kg once a day × 10 days was 31.3%-35.7% (t=2.22, 2.49, P ＜ 0.05). The mammary adenoma-inhibiting rate of 9002# at the dosage of 50 mg/kg once a day × 10 days was 57.1% ( t = 2.63, P ＜ 0.01 ), and that of 9002# at the dosage of 150 mg/kg once a day × 10 days was 48.6% (t= 2.19, P＜0.01). CONCLUSION: 9002# has certain inhibiting effects on transplanting sarcomas in IRM-2 inbred strain mice, and the drug at the dosage 50 mg/kg once a day × 10 days is more effective on both sarcomas. 9002# has potential value in clinical cancer treatment.